分子肿瘤学国家重点实验室焦宇辰课题组，长期围绕肿瘤临床诊疗的核心问题，主要从事消化系统和神经系统恶性肿瘤的癌症基因组、分子分型及无创活检研究，筛选可用于临床诊疗的分子标志物。 目前，课题组包含研究员焦宇辰，副研究员王小兵、刘梅，主管技师李茉，技师张滢，以及十余名硕士和博士研究生。

1. 2020.1-2023.12， 国自然科学基金面上项目，LKB1/TNIK信号轴调控结直肠癌转移的机制研究，课题编号：81972767；金额：55万。

2. 2016.1-2016.12， 国自然科学基金应急管理项目，MiR-486-5p调控肝癌细胞上皮间质转化和肿瘤微环境变化的机制及其临床意义, 课题编号：81641113；金额：10万。

3. 2013.1-2015.12，国自然科学基金青年基金，miR-492影响宫颈癌细胞放化疗敏感性的机制研究, 课题编号：81302279；金额：23万。

1. 2020.1-2023.12， 国自然科学基金面上项目，LKB1/TNIK信号轴调控结直肠癌转移的机制研究，课题编号：81972767；金额：55万。

2. 2016.1-2016.12， 国自然科学基金应急管理项目，MiR-486-5p调控肝癌细胞上皮间质转化和肿瘤微环境变化的机制及其临床意义, 课题编号：81641113；金额：10万。

3. 2013.1-2015.12，国自然科学基金青年基金，miR-492影响宫颈癌细胞放化疗敏感性的机制研究, 课题编号：81302279；金额：23万。

[1] ZhangY, Li N, Yuan G, Yao H, Zhang D, Li N, Zhang G, Sun Y, Wang W, Zeng J, Xu N, LiuM*, Wu L. Upregulation NOD1 and NOD2 contribute to cancer progressionthrough the positive regulation of tumorigenicity and metastasis in humansquamous cervical cancer. BMC Medicine. 2022;20(1):55. 

[2] Pan S, Yin K, Tang Z, Wang S, Chen Z,Wang Y, Zhu H, Han Y, Liu M*, Jiang M*, Xu N*, Zhang G*.Stimulation of hypothalamic oxytocin neurons suppresses colorectal cancerprogression in mice. Elife. 2021;10:e67535. 

[3] Wang Y, Liu X, Hu G, Hu C, Gao Y, HuoM, Zhu H, Liu M*, Xu N*. EGFR-IL-6 signaling axis mediated the inhibitoryeffect of methylseleninic acid on esophageal squamous cell carcinoma. Front. Pharmacol. 2021;12:719785. 

[4]Liu J, Kuang S, Zheng Y, Liu M*, Wang L*. Prognostic andpredictive significance of the tumor microenvironment in hepatocellularcarcinoma. CancerBiomark. 2021;32(1):99-110. 

[5]Tan B#, Liu M#, Wang L, Wang J, Xiong F,Bao X, Gao Y, Yu L, Lu J*. Serum microRNAs predict response of patients withchronic hepatitis B to antiviral therapy. Int J Infect Dis. 2021;108:37-44. (co-firstauthor) 

[6]Hu G, Wang S, Wang Y, Gao Y, Zhu H, LiuM*, Xu N*, Wang L*.Clinical andfunctional significance of CHK1-S, an alternatively spliced isoform ofthe CHK1 gene, in hepatocellular carcinoma.J Cancer. 2020;11(7):1792-1799. 

[7]Wang S, Ma K, Zhou C, Wang Y, Hu G, Chen L, Li Z, Hu C, Xu Q, Zhu H, Liu M*, Xu N*.LKB1 and YAP phosphorylation play important roles in Celastrol-inducedβ-catenin degradation in colorectal cancer. Ther Adv Med Oncol. 2019. doi:10.1177/1758835919843736. 

[8]Bi C#, Liu M#,Rong W, Wu F, Zhang Y, Lin S, Liu Y, Wu J, Wang L. High Beclin-1 and ARID1Aexpression corelates with poor survival and high recurrence in intrahepaticcholangiocarcinoma: a histopathological retrospective study. BMC Cancer. 2019;19(1):213.(co-first author) 

[9]Liu M, et al. MicroRNA-492overexpression involves in cell proliferation, migration and radiotherapyresponse of cervical squamous cell carcinomas. Mol Carcinog. 2018;57(1):32-43. 

[10]Zhu W#, Liu M#,et al. Dynamics of circulating microRNAs as a novel indicator of clinicalresponse to neoadjuvant chemotherapy in breast cancer. Cancer Med. 2018;7(9):4420-4433.(co-first author) 

[11]Liu M, et al. Expression ofMicro-RNA-492 (MiR-492) in Human Cervical Cancer Cell Lines is Upregulated byTransfection with Wild-Type P53, Irradiation, and 5-Fluorouracil Treatment InVitro. MedSci Mon. 2018;24:7750-7758. 

[12]Chen       L, Wang S,Wang Y, Zhang W, Ma K, Hu C, Zhu H, Liang S, Liu M*, Xu N*. IL-6 influences the polarization ofmacrophages and the formation and growth of colorectal tumor. Oncotarget. 2018;9:17443-17454.

[13] Liu M,et al. A Preoperative Measurement of Serum MicroRNA-125bMay Predict the Presence of Microvascular Invasion in Hepatocellular CarcinomasPatients. TranslOncol. 2016;9(3), 167–172. 

[14] Wang S, Ma K, Chen L, Zhu H, LiangS, Liu M*, Xu N*. TAZpromotes cell growth and inhibits Celastrol-induced cell apoptosis. Biosci Rep.2016;36(5). pii: e00386. 

[15]Liu M, et al. Methylseleninic acid activates Keap1/Nrf2pathway via up-regulating miR-200a in human esophageal squamous cell carcinomacells. BiosciRep. 2015;35(5). pii: e00256. 

[16] Wang L, Liu M, et al.Identification of recurrence-related serum microRNAs in hepatocellularcarcinoma following hepatectomy. Cancer Biol Ther.2015;16(10):1445-52. (co-first author) 

[17]Liu M, et al. Associationof serum microRNA expression in hepatocellular carcinomas treated withtransarterial chemoembolization and patient survival. PLoS One. 2014;9(10):e109347. 

[18] Li Q, Liu M, et al. CirculatingmiR-19a and miR-205 in serum may predict the sensitivity of luminal A subtypeof breast cancer patients to neoadjuvant chemotherapy with epirubicin pluspaclitaxel. PLoSOne. 2014;9(8):e104870. (co-firstauthor) 

[19] Liu M, et al. MicroRNA-mRNAfunctional pairs for cisplatin resistance in ovarian cancer cells. Chin J Cancer.2014;33(6):285-94. 

[20] Liu M, et al. c-Myc suppressed E-cadherin through miR-9 at thepost-transcriptional level. Cell Biol Int. 2013;37(3):197-202. 

[21] Liu M,et al. TNFa is anovel target of miR-19a. Int J Oncol. 2011;38:1013-22. (引用98次)

[22] LiuM, et al. EB1 acts as an oncogene via activatingbeta-catenin/TCF pathway to promote cellular growth and inhibit apoptosis. Mol Carcinog.2009;48:212-9. (IF=3.571)